BLRX News and Press, BioLineRx Ltd. From 11/05/23

2023-11-05 02:15:00 ET Summary Jiangsu Hengrui Pharma out-licensed global rights (ex-China) for its next-gen PARP1 inhibitor to Germany’s Merck KGaA. BioLineRx, an Israeli biotech, out-licensed China rights to a stem cell mobilizer for multiple myeloma and stem cell disease...

BioLineRx entered Exclusive License Agreement to Motixafortide in Asia, advisored by M.S.Q. Ventures Canada NewsWire NEW YORK , Oct. 31, 2023 /CNW/ -- M.S.Q. Ventures ("MSQ") is pleased to announce that its client, BioLineRx Ltd. ("BioLineRx") (NASDAQ/TAS...

2023-10-12 09:43:09 ET More on biolinerx BioLineRx gains after winning first FDA approval BioLineRx GAAP EPS of -$0.02 Seeking Alpha’s Quant Rating on biolinerx For further details see: BioLineRx announces closing of exclusive license agreement wit...

BioLineRx Announces Closing of Exclusive License Agreement to Motixafortide in Asia and Concurrent Strategic Equity Investment PR Newswire - License agreement includes $15 million upfront, up to $50 million in potential development and regulatory milestones; up to ~$...

2023-10-09 10:00:00 ET More on Health Care Select Sector SPDR Citi turns cautious on pharmaceuticals and biotech BofA Securities: Which small cap non-earner stocks to avoid For further details see: Bioline Rx, Clever Leaves among healthcare movers

2023-10-09 08:23:30 ET More on InMode, Mirati Therapeutics, etc. InMode: Bullish Support Failed To Materialize InMode: Strong Net Cash Position Sets The Stage For Opportunistic Buybacks InMode: Be Greedy When Others Are Fearful Bristol-Myers Squibb to acquire...

2023-10-04 09:59:33 ET More on Health Care Select Sector SPDR September Labor Report Preview: Full Employment To Infinity Stagflation Playbook: Short Tech (QQQ/ARKK) And Long Healthcare (XLV) Citi turns cautious on pharmaceuticals and biotech BofA Securities:...

BioLineRx Announces Encouraging Data from Pilot Phase of Phase 2 Combination Clinical Trial with Motixafortide in First-Line Pancreatic Cancer (PDAC) PR Newswire - 6 of 11 Patients in the Pilot Phase Experienced a Partial Response, with 4 Confirmed; One Patient Exper...

2023-09-21 10:00:13 ET More on Health Care Select Sector SPDR Stagflation Playbook: Short Tech (QQQ/ARKK) And Long Healthcare (XLV) Health Care Select Sector SPDR ETF declares quarterly distribution of $0.5395 BofA clients were net buyers of U.S. equities for a fifth...

BioLineRx Announces Acceptance of Oral Presentation on Pilot Phase Data from Phase 2 Combination Clinical Trial with Motixafortide in First-Line PDAC at AACR Special Conference on Pancreatic Cancer PR Newswire Abstracts to be Published on American Association of Cancer Researc...